X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/mezzion-pharmaceuticals-announces-dr-rahul-rathod-of-boston-childrens-hospital-and-harvard-medical-school-as-the-global-principal-investigator-for-the-confirmatory-pivotal-phase-3-trial-fuel-2-302077629.html
https://www.prnewswire.com/news-releases/mezzion-pharma-raises-nearly-40m-to-advance-a-first-to-market-treatment-option-for-fontan-patients-301807071.html
https://www.prnewswire.com/news-releases/mezzion-pharma-submits-protocol-for-confirmatory-pivotal-phase-3-trial-fuel-2-in-fontan-subjects-301751245.html
https://www.prnewswire.com/news-releases/mezzion-pharma-receives-clear-fda-path-forward-for-the-approval-of-udenafil-for-single-ventricle-heart-disease-301558085.html
https://www.prnewswire.com/news-releases/mezzions-new-drug-application-nda-for-its-orphan-drug-udenafil-for-the-treatment-of-single-ventricle-heart-disease-svhd-has-been-accepted-for-filing-by-the-fda-301299410.html
https://www.prnewswire.com/news-releases/mezzion-announces-re-submission-of-new-drug-application-for-its-orphan-drug-udenafil-to-treat-patients-who-have-undergone-the-fontan-operation-for-single-ventricle-heart-disease-301257235.html
https://www.prnewswire.com/news-releases/mezzion-announces-submission-of-new-drug-application-for-its-orphan-drug-udenafil-to-treat-patients-who-have-undergone-the-fontan-operation-for-single-ventricle-heart-disease-301086011.html
https://www.prnewswire.com/news-releases/mezzion-pharma-announces-top-line-data-from-fuel-will-be-presented-at-the-american-heart-association-aha-late-breaking-scientific-sessions-in-philadelphia-pa-november-17-2019-300950344.html
https://www.prnewswire.com/news-releases/mezzion-pharma-announces-that-it-has-conducted-a-type-c-meeting-with-the-fda-regarding-the-top-line-data-from-the-fuel-phase-3-clinical-trial-300936949.html
Market Place
Share 
